Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-05-25
1996-04-30
Higel, Floyd D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
5142355, 5142358, 5142365, 5142368, 5142372, A61K 31535, C07D41300
Patent
active
055125700
ABSTRACT:
Substituted heterocycles of the structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, emesis and nausea.
REFERENCES:
patent: 2943022 (1960-06-01), Siemer et al.
patent: 3005818 (1961-10-01), Siemer et al.
patent: 3458509 (1969-07-01), Levine et al.
patent: 3506673 (1970-04-01), Warawa et al.
patent: 3541090 (1970-11-01), Herlinger et al.
patent: 4010266 (1977-03-01), McLoughlin et al.
patent: 4360519 (1982-11-01), White et al.
patent: 4705553 (1987-11-01), Buschmann et al.
patent: 4782054 (1988-11-01), Regnier et al.
patent: 4943578 (1990-07-01), Naylor et al.
patent: 5064838 (1991-11-01), Carr et al.
patent: 5095021 (1992-03-01), Zipplies et al.
Siemer, et al., "Analgesic 1--phenyl--2,3 dimethyl--4--morpholinomethyl--3--pyrazolin--5--ones".
Chem. Abstracts, 56, (6), p. 5977 (1962.
Sinkula, et al., "Rationale for Design of Biologically Reversible Drug Derivatives: Prodrugs", J. Pharm. Sciences, 64 (2), pp. 181-210 (1975).
Svensson, "Prodrugs: metabolism-based drug design" Pharmaceutisch Weekblad, 122, pp. 245-250, (1987).
Bountra, et al., "Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets", Eur. J. Pharmacol., 249, R3-R4 (1993).
Tattersall et al., "Enantioselective Inhibition of Apomorphine-induced Emesis in the Ferret by the Neurokinin 1 Receptor Antagonist CP-99,994", Neuropharmacol., 33(2), 259-260 (1994).
Watson, et al., "The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor", British J. Pharmacol., 115, 84-94 (1995).
Advenier, et al., "Neurokinin A (NK2) Receptor Revisited with SR 48968 . . . ", Biochem. and Biophys. Res. Comm., 184(3), pp. 1418-1424 (1992).
Balant, et al., "Prodrugs for the improvement of drug absorption via different routes of administration.", Eur. J. Drug Metab. Pharmaco., 15(2), pp. 143-153, (1990).
Bodar, et al., "Novel Approaches in Prodrug Design", Drug Future, VI(3), pp. 165-182 (1981).
Bundgaard, "The double prodrug concept and its applications", Adv. Drug Delivery Rev., 3 pp. 39-65, (1989).
Edmonds-Alt, et al., "A Potent and Selective Non-PeptideAntagonist of the Neurokinin A (NK2) Receptor", Life Sciences., 50, pp. PL101-PL106 (1992).
Frossard, et al., "Tachykinin Receptors and the Airways", Life Sciences., 49, pp. 1941-1953, (1991).
Guthrie, et al., "The Use of Periodate-oxidised Glycosides in the Robinson-Schopf . . . ", J. Chem. Society, vol. C(1), pp. 62-66 (1967).
Howson, et al., "An SAR Study for the Non-Peptide Substance P. Receptor . . . ", Biorganic & Medicinal Chemistry Letters, 2(6, pp. 559-564, (1992).
Lowe, et al., "The Discovery of (2S,3S)--cis--2--(Diphenylmethyl)--N-- (2--methoxyphenly) methyl!. . . ", J. Meed. Chem. 35, pp. 2591-2600, (1992).
McCormick, "Properties of Periodate-Oxidised Polysaccharides", Part VII. . . . , J. Chem. Society, C(23), pp. 2121-2127, (1966).
Montgomery, et al., "2--Fluropurine Ribonucleosides", J. Med. Chem., 13(3), pp. 421-427 (1970).
Payan, et al., "Substance P. Recognition by a Subset of Human T Lymphocytes", J. Clin. Invest., 74, 1532-1539 (1984).
Peyronel, et al., "Synthesis of RP-67,580, a New Potent Nonpeptide Substance P Antagonist", Biorganic and Med. Chem. Lett. 2(1), pp. 37-40, (1992).
Dorn Conrad P.
Hale Jeffrey J.
Maccoss Malcolm
Mills Sander G.
Higel Floyd D.
Merck & Co. , Inc.
Rose David L.
Thies J. Eric
LandOfFree
Treatment of emesis with morpholine tachykinin receptor antagoni does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of emesis with morpholine tachykinin receptor antagoni, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of emesis with morpholine tachykinin receptor antagoni will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-628927